Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice
Authors' conclusion
ETI therapy impacted CFRD in clinical practice reducing insulin needs and improving glycemic control measured by HbA1c and CGM. The improvements can be observed from the first 3 months of treatment.
Study context
- Population
- Adults with Cystic Fibrosis Related Diabetes (CFRD) and at least one F508del mutation starting elexacaftor/tezacaftor/ivacaftor (ETI) in clinical practice
- Participants
- 23 adults
- Exposure
- Before vs after ETI initiation
- Outcome
- HbA1c change
- Follow-up
- 3 months
Main finding
As reported in the abstract
HbA1c significantly improved by 0.3% (0.1-0.5) after 3 months of ETI (p = 0.004)
0.3 %
Observational data: associations, not effects.
Further findings
Proportion of patients needing MDI
- Reduced by 16 % (p = 0.023)
Total daily insulin dose
- Dropped by 0.12 (0.05-0.18) UI/kg/day (p < 0.001)
- 0.12 UI/kg/day
Flash Continuous Glucose Monitoring (CGM) data in insulin-treated patients
- Unchanged after insulin reduction, except Time In Tight Range 70–140 mg/dL increased 8 % (0.3-15.6) (p = 0.043)
Original publication
Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pract. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →